Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO
In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.
In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.